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Abstract 
 
Background: In 2012, National Institute for Health and Care Excellence (NICE) 
Clinical Guidelines for Epilepsies: Diagnosis and Management (CG137) included, for 
the first time, ketogenic diets (KDs) as a treatment option for drug resistant paediatric 
epilepsy.  The recommendation was made to refer children and young people with 
epilepsy whose seizures have not responded to appropriate anti-epileptic drugs to a 
tertiary paediatric epilepsy specialist for consideration of the use of KDs.  We aimed 
to assess the impact of this change in guidance on numbers of ketogenic centres 
and patients following KDs for epilepsy in the UK and Ireland.  
Methods: An online survey was circulated to ketogenic dietitians from the UK and 
Ireland. Results were compared with similar surveys published in 2000 and 2010.  
Results: The number of centres offering KDs for treatment of epilepsy has risen 
from 22 in 2000, to 28 in 2010 to 39 in 2017 (77% overall increase). Seven of these 
centres accept adult referrals, in comparison to only two centres in 2010. Patient 
numbers have increased from 101 in 2000 to 754 in 2017. 267 patients are waiting to 
commence KD at 31 centres.  
Conclusions: Over the last seven years, the number of patients treated with a KD 
for epilepsy in the UK and Ireland has increased by 647%, with a 77% increase in 
the number of centres offering KDs. Despite this rapid growth, there is ongoing 
demand for patients to be considered for dietary therapy, highlighting the need for 
continued expansion of KD services nationally.  
 
 
 
Introduction 
Ketogenic diets (KDs) are high-fat, restricted carbohydrate diets that have been used 
as a treatment for drug-resistant epilepsy since the 1920s (1). There are different 
types of KDs in use: the classical KD (CKD) (2), medium chain triglyceride (MCT) KD 
(3), Modified Atkins diet (MAD) (4) modified ketogenic diet (MKD) (5, 6)  and the low 
glycaemic index treatment (LGIT) (7). The MAD, MKD and LGIT are less restrictive 
versions of a KD, often using household measures rather than accurate weighing of 
foods, and greater freedom in consumption of protein and, in some cases, 
carbohydrate. This more liberal approach may help improve tolerability and 
adherence (8), but the principles of a high-fat, low-carbohydrate diet remain, requiring 
significant dietary adjustment for the child, young person or adult undertaking KD 
therapy. 
 
KDs are a well-established non-pharmacological treatment for drug resistant 
epilepsy evidenced by an increasing number of randomised controlled trials (RCTs) 
in the paediatric population. The most recent Cochrane review (2018) (8) concluded 
that evidence from 10 trials showed promising results for the use of KDs in epilepsy 
treatment. ≥50% seizure reduction was achieved in  38-85% (9, 10) of participants 
treated with classical 4:1 KD and 42-60% (11, 12) treated with MAD for a duration of 3 
months. Seizure freedom varies with 1-55% (9, 10) of participants following a classical 
KD and 10-25%  (11, 12) following a MAD for 3 months achieving this. 
 
KDs are being increasingly used for adults with epilepsy and both the classical KD 
and MAD show promise in terms of feasibility and tolerability (13-15). Effectiveness 
was recently assessed in two  RCTs comparing MAD to control (treatment as usual). 
Zare et al. (16) reported  35.3%  of participants to be responders achieving  >50% 
reduction in seizure frequency after 2 months treatment with MAD.  In contrast, 
Kverneland et al. (17) found only 12.5% of participants experienced >50% seizure 
reduction after 3 months treatment with MAD. However, this finding was not 
statistically significant. At best, they report a significant reduction in diet versus 
control group for moderate benefit only (25-50% seizure reduction). Low participant 
numbers, epilepsy type (focal versus generalised) and length of time with drug 
resistant epilepsy are possible reasons for difference in findings.  Further, large scale 
RCTs are required in this area.    
 
  
The use of KDs to treat childhood epilepsy in the UK was examined in 2000 (18) and 
then again in 2010 (19) via a survey to paediatric ketogenic dietitians. The number of 
centres offering KDs and patients following a KD increased in this time period. These 
surveys were undertaken prior to 2012 and the publication of the National Institute 
for Health and Care Excellence (NICE) guidance on the diagnosis and management 
of epilepsies (CG137; 2012) (20) which, for the first time, recommended consideration 
of a KD for children and young people with drug resistant epilepsy . One may expect 
that referrals for KD therapy and demand on KD services would have increased 
further since the change in NICE guidance (20). This survey aimed to reassess the 
use of KDs aiming to assess the changes in practice and service provision since 
2007. 
 
Methods 
An online survey was devised by a group of adult and paediatric ketogenic dietitians, 
as part of the Ketogenic Dietitians Research Network (KDRN). The survey 
comprised 44 questions (Appendix 1) including questions regarding the number of 
services offering KD therapy, number and age of patients treated, waiting time to 
commence KD, duration on KD and types of KD in use.  The survey was circulated 
via the KDRN and Ketogenic Professional Advisory Group (KetoPAG) mailing lists 
and advertised through the parental support charities, Matthew’s Friends and The 
Daisy Garland. Each service was asked to complete only one survey. Data were 
collected in July 2017 and approved by the audit and research departments of 
individual centres as required. The results were compared with the findings of earlier 
surveys published in 2000 (18) and 2010 (19).    
 
 
Results 
Demographics 
Twenty-five KD services across the UK and Ireland completed the full survey. An 
additional 14 KD services provided data on the number of patients being treated with 
KD and those waiting to commence treatment but declined or were unable to 
complete the full survey for unreported reasons. 
 
Ketogenic diet services  
The number of services offering KDs for the treatment of epilepsy grew from 22 in 
2000, (18) to 28 in 2010 (19), to 39 in 2017 representing a 77% increase (Figure 1).  
 
Figure 2 shows the 39 centres in the UK and Ireland offering a service in 2017, with 
comparative size and patient group (paediatric, adult or both) treated. Two services 
offered KD therapy to adults in 2010 (19), compared with seven in 2017. 
 
 
Number of patients 
The number of patients with epilepsy being treated with a KD increased from 101 in 
2000 (18), to 152 in 2010 (19), to 754 in 2017 (Figure 3) over a seven-fold increase. 
Thirty-one services had a waiting list, with 276 patients in total (range 1-49) waiting 
to commence a KD. 
 
Types of KDs used  
Twenty-six (of 39) ketogenic services responded to this section of the survey. 
324/580 (55.9%) patients were following a classical KD, 187/580 (32.2%) MKD, 
56/580 (9.7%) MCT KD and 13/580 (2.2%) LGIT (Figure 4a). The classical and MCT 
KDs were the only diets in use in 2000 (18) and 2010 (19). 
 
In 2017, of the 324 patients following a classical KD, 142 (43.8%) were orally fed, 36 
(11.2%) were enterally and orally-fed, and 146 (45%) were fully enterally-fed. Of the 
187 patients following MKD, 183 (97.9%) patients fed orally, 3 (1.6%) were both 
enterally and orally-fed, and 1 (0.5%) were fully enterally-fed. Of the 56 patients 
following MCT KD, 40 (71.4%) fed orally, 8 (14.2%) were enterally and orally-fed, 
and 8 (14.2%) were fully enterally-fed. 13 (100%) patients were following a LGIT 
orally. No service reported use of the MAD (Figure 4b).  
 
 
KD initiation 
180/580 (31%) of patients commenced a KD in the acute hospital setting which is 
similar to 43/132 (33%) of patients in 2010 (19) and 52/101 (51%) in 2000(18). The 
remainder commenced a KD at home as an outpatient.  
 
KD service provision 
7/26 (27%) of ketogenic services were supported by charity funding, with the 
remainder funded predominantly by the heath service. Almost half of all ketogenic 
services reported inadequate funding for dietitians 11/26 (42%), with some centres 
reporting inadequate funding for nurses 3/26 (12%) and consultants 2/26 (8%) which 
has limited service provision for new patients.  176/580 (30.3%) patients were 
treated with a KD for over 2 years and 4 services stated that this extended use of KD 
treatment, limited their service provision for new patients. Only 5 services had 
access to a transition service for children ≥18 years; the shortage of transition 
services also limited ketogenic service provision.  
 
Discussion 
The number of KD services has increased by over two thirds since 2000, with a 
concomitant increase of 647% in patient numbers. This is likely due, in part, to the 
growing body of evidence supporting use of the KD for epilepsy (8) and the inclusion 
of KDs in NICE guidance (20). A similar study of French KD services (21) also reports 
an increase in the number of KD services and patients treated from 2005 to 2018.  
 
Use of the classical KD has reduced substantially since 2000, predominantly 
replaced with the MKD, which almost half of all orally-fed patients in this survey are 
following. Despite the lack of published evidence for the effectiveness of MKD for 
epilepsy, use of this KD variant may have increased as it is viewed as easier to 
implement by dietitians, reducing the dietetic time required to calculate the dietary 
prescription and to educate patients (8).  The less restrictive MKD may be better 
tolerated and have higher compliance levels compared with the classical and MCT 
KDs, but further research is needed to support this and to determine its efficacy for 
epilepsy. 
 
In 2000, it was common practice to initiate KD in the acute hospital setting (18) and 
the original International Consensus Statement (2009) (22) on Optimal Clinical 
Management of KDs in epilepsy supported this practice. In 2010 (19), half of all 
responding centres initiated KDs on an outpatient basis. This trend continued in our 
survey, with the majority of ketogenic services in the UK and Ireland favouring 
outpatient KD initiation. The patients who commenced KD in the acute setting may 
have been admitted for other reasons, including poor epilepsy control rather than 
exclusively to start a KD. Commencing a KD as an outpatient is generally less 
resource intensive for the service and is likely to be less of a burden for families.  
 
Although not yet recommended as part of current NICE guidance, there has been an 
increase in availability of adult services. Research into KD use in this patient group 
increases (16, 17, 24)., although studies are limited by small sample sizes and there 
remains a need for a large scale RCT exploring clinical and cost effectiveness. Our 
survey has highlighted that a third of patients on a KD remain on diet over the 
recommended two year treatment period (23), which could contribute to the greater 
demand for adult services.  Disappointingly, despite the introduction of some adult 
services, only 5/26 (19%) of paediatric centres stated they had access to an adult or 
transition service to refer their older patients (≥18 years) to. This is an ongoing 
challenge for the managing paediatric ketogenic team but more significantly, the 
family who may have to consider weaning their child from KD, even when a positive 
response is still maintained.  
 
The present study has some limitations. The survey was not validated and could be 
subject to reporter bias. Whilst, this was a practical and cost-efficient method of 
contacting nationwide ketogenic services, missing or incomplete data are inevitable, 
and the time restraints of clinical practice may have limited the depth of response on 
some occasions. On analysing the data this provided more questions; how long 
patients are waiting to access KD services, why are patients staying on diet over 2 
years and what service adjustments or improvements are being implemented to 
reduce waiting lists or waiting times. 
 
In conclusion, there is ongoing demand for KD for both paediatric and adult patients. 
Despite the rapid increase in services and increased availability of the diet, there are 
still substantial waiting lists, highlighting the need for continued expansion of 
services nationally.  With almost 80% of services stating that the service size is 
limited by funding, new models of service delivery and funding need to be found to 
ensure that patients can access an effective treatment in a timely manner. 
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